Company / Operating Cash Flow
Outlook Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$68.8M
FY2025
5-year range
-$68.8M / -$15.5M
FY2021-FY2025
Trend
-113.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 6 years, ranging from -$69M in FY2025 to -$16M in FY2018.
Based on SEC 10-K filings.
-$69M in FY2025.
Declined from -$33M to -$69M over the past 6 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 113.1% year-over-year.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$68.8M | -113.1% |
| FY2020 | -$32.3M | +2.3% |
| FY2019 | -$33.0M | -113.1% |
| FY2018 | -$15.5M | +65.9% |
| FY2017 | -$45.5M | -65.5% |
| FY2016 | -$27.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026